Jade Biosciences (JBIO) Equity Ratio (2020 - 2026)

Jade Biosciences has reported Equity Ratio for 7 years, with the latest figure at 0.93 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 186.17% year-over-year to 0.93; the trailing twelve-month figure through Mar 2026 stood at 0.93 (up 186.17% YoY), and the FY2025 full-year result was 0.95, up 247.88% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.93, down from 0.95 in the prior quarter.
• The five-year high for Equity Ratio was 0.97 in Q2 2022, with the low at 1.08 in Q1 2025.
• Historically, Equity Ratio has averaged 0.59 across 5 years, with a median of 0.9 in 2025.
• The largest YoY upside for Equity Ratio was 17165.71% in 2025 against a maximum downside of 226.57% in 2025.
• Jade Biosciences' Equity Ratio stood at 0.94 in 2022, then slipped by 8.3% to 0.86 in 2023, then slumped by 174.83% to 0.64 in 2024, then soared by 247.88% to 0.95 in 2025, then decreased by 2.37% to 0.93 in 2026.
• The last three Equity Ratio figures came in at 0.93 (Q1 2026), 0.95 (Q4 2025), and 0.89 (Q3 2025), per Business Quant data.